Boston-based Activ Surgical designed ActivSight to provide enhanced visualization and real-time, on-demand surgical insights. The module attaches to laparoscopic and robotic systems and integrates with standard monitors in the operating room. It received CE mark approval for ActivSight in December 2022. The FDA cleared the technology in April 2021.
The company aims to transform the surgical experience using emerging technologies and data. It wants every surgical imaging system to deliver intelligent information, reducing surgical complication rates. Activ Surgical announced the first U.S. case with the AI-enabled platform just over a year ago.
Activ Surgical says its platform transforms the operating room by seamlessly upgrading existing equipment while serving as the “eyes” for the surgeons using it. They can now access critical intraoperative data as augmented reality overlays.
Dr. Mohamad Rassoul Abu-Nuwar performed the latest procedure at Abdali Hospital in Amman, Jordan. The doctor performed a surgical bariatric revision using ActivSight’s ActivPerfusion mode on Dec. 24, 2023.
“West Penn was among the first hospitals where we launched ActivSight in 2022,” said Manisha Shah-Bugaj, Activ Surgical CEO. “Now, with Dr. Abu-Nuwar championing our technology at Abdali Hospital and the support of one of our lead investors, Hikma Ventures, we are able to deliver intelligent information to doctors beyond the U.S. to reduce surgical complication rates. As we continue to achieve significant milestones such as this, our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make cutting-edge surgery accessible for all.”
